Central Nervous System Lymphoma

 

 Buy Article Permissions and Reprints

Abstract

Central nervous system lymphoma (CNSL) is a rare and aggressive malignancy that primarily affects the brain, spinal cord, and meninges. This article provides a comprehensive overview of the current understanding of CNSL encompassing its epidemiology, pathophysiology, clinical presentation, diagnosis, treatment modalities, and prognosis. Although the main focus is on primary CNS lymphoma (PCNSL), ocular lymphoma, primary leptomeningeal lymphoma, and secondary CNS lymphoma are also discussed. The pathobiology of CNSL involves the infiltration of malignant lymphocytes within the CNS parenchyma or leptomeninges. Various risk factors and immunological mechanisms contribute to its development, including immunodeficiency states, chronic inflammation, and genomic alterations. Accurate diagnosis is crucial for appropriate management, given the heterogeneous clinical presentation. The neuroimaging, systemic imaging, and other modalities for diagnosis and evaluation for extent of disease involvement will be discussed. Additionally, the importance of histopathological examination, cerebrospinal fluid (CSF) analysis, and molecular testing in confirming the diagnosis and guiding treatment decisions are highlighted. The treatment landscape for CNSL has evolved significantly. Therapeutic approaches encompass a multimodal strategy combining high-dose methotrexate-based chemotherapy, consolidation with whole-brain radiation therapy, and high-dose chemotherapy with stem cell rescue. Recent advancements in targeted therapies and immunomodulatory agents offer promising avenues for future treatment options. We review the clinical outcomes and prognostic factors influencing the survival of CNSL patients, including age, performance status, disease stage, and genetic abnormalities.

Publication History

Article published online:
23 November 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Lauw MIS, Lucas CG, Ohgami RS, Wen KW. Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features. Diagnostics (Basel) 2020; 10 (12) 1076
  CrossrefPubMedGoogle Scholar
• 2 Ruggieri S, Tamma R, Resta N. et al. Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma. Oncotarget 2017; 8 (19) 31254-31269
  CrossrefPubMedGoogle Scholar
• 3 Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013; 9 (06) 317-327
  CrossrefPubMedGoogle Scholar
• 4 Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol 2017; 35 (21) 2410-2418
  CrossrefPubMedGoogle Scholar
• 5 Grommes C. Central nervous system lymphomas. Continuum (Minneap Minn) 2020; 26 (06) 1476-1494
  PubMedGoogle Scholar
• 6 Hernández-Verdin I, Morales-Martínez A, Hoang-Xuan K, Alentorn A. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies. Curr Opin Neurol 2022; 35 (06) 779-786
  CrossrefPubMedGoogle Scholar
• 7 Mo SS, Cleveland J, Rubenstein JL. Primary CNS lymphoma: update on molecular pathogenesis and therapy. Leuk Lymphoma 2023; 64 (01) 57-65
  CrossrefPubMedGoogle Scholar
• 8 Gandhi MK, Hoang T, Law SC. et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood 2021; 137 (11) 1468-1477
  CrossrefPubMedGoogle Scholar
• 9 Molnár PP, O'Neill BP, Scheithauer BW, Groothuis DR. The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death. Neuro-oncol 1999; 1 (02) 89-100
  CrossrefPubMedGoogle Scholar
• 10 Barajas RF, Politi LS, Anzalone N. et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-oncol 2021; 23 (07) 1056-1071
  CrossrefPubMedGoogle Scholar
• 11 Grimm SA, McCannel CA, Omuro AM. et al. Primary CNS lymphoma with intraocular involvement: international PCNSL Collaborative Group Report. Neurology 2008; 71 (17) 1355-1360
  CrossrefPubMedGoogle Scholar
• 12 Shenkier TN, Blay JY, O'Neill BP. et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23 (10) 2233-2239
  CrossrefPubMedGoogle Scholar
• 13 Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol 2013; 70 (03) 311-319
  CrossrefPubMedGoogle Scholar
• 14 Ferreri AJM, Calimeri T, Lopedote P. et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 2021; 193 (03) 497-505
  CrossrefPubMedGoogle Scholar
• 15 Abrey LE, Batchelor TT, Ferreri AJ. et al; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23 (22) 5034-5043
  CrossrefPubMedGoogle Scholar
• 16 Fox CP, Phillips EH, Smith J. et al; British Society for Haematology. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 2019; 184 (03) 348-363
  CrossrefPubMedGoogle Scholar
• 17 Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood 2022; 140 (09) 971-979
  CrossrefPubMedGoogle Scholar
• 18 Sheng X, Xu M, Li X. A case of primary central nervous system lymphoma mimic neuromyelitis optica. Transl Neurosci 2020; 11: 28-33
  CrossrefPubMedGoogle Scholar
• 19 Chan CC, Rubenstein JL, Coupland SE. et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16 (11) 1589-1599
  CrossrefPubMedGoogle Scholar
• 20 Kwok HM, Li KY, Chan RLS. et al. Different facets of intracranial central nervous system lymphoma and its imaging mimics. J Clin Imaging Sci 2022; 12: 4
  CrossrefPubMedGoogle Scholar
• 21 Santos E, Scolding NJ. Neurolymphomatosis mimicking neurosarcoidosis: a case report. J Med Case Rep 2010; 4: 5
  CrossrefPubMedGoogle Scholar
• 22 Ferreri AJ, Blay JY, Reni M. et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21 (02) 266-272
  CrossrefPubMedGoogle Scholar
• 23 Abrey LE, Ben-Porat L, Panageas KS. et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24 (36) 5711-5715
  CrossrefPubMedGoogle Scholar
• 24 Zhu JJ, Gerstner ER, Engler DA. et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-oncol 2009; 11 (02) 211-215
  CrossrefPubMedGoogle Scholar
• 25 Rubenstein JL, Hsi ED, Johnson JL. et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31 (25) 3061-3068
  CrossrefPubMedGoogle Scholar
• 26 Omuro A, Correa DD, DeAngelis LM. et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015; 125 (09) 1403-1410
  CrossrefPubMedGoogle Scholar
• 27 Ferreri AJM, Cwynarski K, Pulczynski E. et al; IELSG32 Study Investigators. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 2022; 36 (07) 1870-1878
  CrossrefPubMedGoogle Scholar
• 28 Scordo M, Wang TP, Ahn KW. et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol 2021; 7 (07) 993-1003
  CrossrefPubMedGoogle Scholar
• 29 Grommes C, Tang SS, Wolfe J. et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 2019; 133 (05) 436-445
  CrossrefPubMedGoogle Scholar
• 30 Ghesquieres H, Chevrier M, Laadhari M. et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol 2019; 30 (04) 621-628
  CrossrefPubMedGoogle Scholar
• 31 Nayak L, Iwamoto FM, LaCasce A. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017; 129 (23) 3071-3073
  CrossrefPubMedGoogle Scholar
• 32 Sen HN, Bodaghi B, Hoang PL, Nussenblatt R. Primary intraocular lymphoma: diagnosis and differential diagnosis. Ocul Immunol Inflamm 2009; 17 (03) 133-141
  CrossrefPubMedGoogle Scholar
• 33 Lachance DH, O'Neill BP, Macdonald DR. et al. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 1991; 41 (01) 95-100
  CrossrefPubMedGoogle Scholar
• 34 Taylor JW, Flanagan EP, O'Neill BP. et al. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology 2013; 81 (19) 1690-1696
  CrossrefPubMedGoogle Scholar
• 35 Orellana-Noia V, Abousaud A. Secondary central nervous system lymphoma: updates in treatment and prophylaxis strategies. Curr Treat Options Oncol 2022; 23 (10) 1443-1456
  CrossrefPubMedGoogle Scholar
• 36 Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. Prevention and management of secondary central nervous system lymphoma. Haematologica 2023; 108 (03) 673-689
  CrossrefPubMedGoogle Scholar